ERBB2 and breast carcinoma: Recently, Tanner et al (2005) showed that the gastric-cancer cell line N87 presenting ERBB2 amplification is as sensitive to trastuzumab as the ERBB2-amplified breast-carcinoma cell line SKBR-3, which is a widely used reference in trastuzumab sensitivity studies (Pegram et al, 1997, 1999).